Alembic Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Market Signals

Technical Trend Overview and Price Movement

On 9 July 2026, Alembic Pharmaceuticals closed at ₹811.10, down 2.39% from the previous close of ₹831.00. The stock’s intraday range was between ₹799.45 and ₹843.00, reflecting heightened volatility. This price action comes against the backdrop of a 52-week high of ₹1,064.70 and a low of ₹635.30, indicating that the stock is currently trading closer to its lower band of the annual range.

The technical trend has shifted from sideways to mildly bearish, signalling a potential weakening in price momentum. This is corroborated by the daily moving averages, which are mildly bearish, suggesting that short-term price averages are trending lower relative to longer-term averages. Such a shift often precedes further downside or consolidation phases.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator presents a mixed signal. On the weekly chart, the MACD remains mildly bullish, indicating some underlying positive momentum over the medium term. However, the monthly MACD is bearish, signalling that longer-term momentum is deteriorating. This divergence between weekly and monthly MACD readings suggests that while short-term traders may find some buying opportunities, the broader trend remains under pressure.

Complementing this, the Know Sure Thing (KST) oscillator is bullish on the weekly timeframe but bearish monthly, reinforcing the notion of short-term strength amid longer-term weakness. This dichotomy is critical for investors to consider when timing entries or exits.

RSI and Overbought/Oversold Conditions

The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This indicates that the stock is neither overbought nor oversold, suggesting a lack of extreme momentum in either direction. The absence of RSI extremes implies that the stock could be poised for a directional move, but confirmation from other indicators is necessary.

Bollinger Bands and Volatility

Bollinger Bands provide insight into volatility and price extremes. On the weekly chart, the bands are mildly bullish, indicating that price is trending towards the upper band, which often signals upward momentum or a potential breakout. Conversely, the monthly Bollinger Bands are bearish, reflecting a longer-term contraction or downward pressure on price. This contrast highlights the stock’s current tussle between short-term optimism and longer-term caution.

Volume and On-Balance Volume (OBV)

Volume analysis through the On-Balance Volume (OBV) indicator is encouraging, with both weekly and monthly OBV readings bullish. This suggests that buying volume is outpacing selling volume, a positive sign that supports price stability or potential recovery. Strong OBV readings often precede price advances, indicating institutional accumulation or sustained investor interest.

Moving Averages and Dow Theory Signals

Daily moving averages have turned mildly bearish, signalling that the short-term trend is weakening. This is a cautionary sign for traders relying on moving average crossovers or trend-following strategies. Meanwhile, Dow Theory assessments provide a more optimistic outlook, with both weekly and monthly readings mildly bullish. This suggests that despite short-term setbacks, the broader market sentiment for Alembic Pharmaceuticals retains some positive undercurrents.

Comparative Performance Against Sensex

Examining Alembic Pharmaceuticals’ returns relative to the Sensex reveals a mixed performance. Over the past week, the stock declined by 1.99%, underperforming the Sensex’s modest 0.54% drop. However, over the last month, Alembic outperformed significantly with an 8.79% gain compared to Sensex’s 4.05%. Year-to-date, the stock has declined 4.37%, but this is less severe than the Sensex’s 10.23% fall, indicating relative resilience.

Longer-term returns show a more challenging picture. Over one year, Alembic’s stock has fallen 18.78%, considerably worse than the Sensex’s 8.61% decline. Over five years, the stock has lost 17.65%, while the Sensex gained 45.53%, highlighting underperformance in the medium term. However, a 10-year return of 35.43% still outpaces many peers, though it lags the Sensex’s 182.02% gain substantially.

Mojo Score and Analyst Ratings

MarketsMOJO assigns Alembic Pharmaceuticals a Mojo Score of 45.0, categorising it as a Sell with a recent downgrade from Hold on 8 July 2026. This downgrade reflects the deteriorating technical parameters and cautious outlook. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often entails higher volatility and risk compared to large-cap peers.

Investment Implications and Outlook

Investors in Alembic Pharmaceuticals should approach with caution given the mixed technical signals and recent downgrade. The mildly bearish daily moving averages and monthly MACD suggest that the stock may face further pressure in the near term. However, bullish weekly momentum indicators such as MACD, KST, and OBV provide some counterbalance, indicating potential for short-term rallies or consolidation phases.

The neutral RSI readings imply that the stock is not currently overextended, leaving room for directional moves either way. Traders may consider monitoring key support levels near ₹799 and resistance around ₹843, which have defined recent price action. A sustained break below support could confirm bearish momentum, while a move above resistance might signal a short-term recovery.

Given the stock’s underperformance relative to the Sensex over the past year and five years, investors should weigh Alembic’s fundamentals and sector outlook carefully. The Pharmaceuticals & Biotechnology sector remains competitive and subject to regulatory and innovation risks, which can impact stock performance.

Overall, Alembic Pharmaceuticals currently exhibits a technical profile that is neither decisively bullish nor bearish but tilted towards caution. Investors with a higher risk tolerance may find opportunities in short-term momentum plays, while more conservative investors might await clearer trend confirmation before committing.

Summary of Key Technical Metrics:

• Current Price: ₹811.10 (down 2.39%)
• Daily Moving Averages: Mildly Bearish
• Weekly MACD: Mildly Bullish; Monthly MACD: Bearish
• Weekly KST: Bullish; Monthly KST: Bearish
• RSI (Weekly & Monthly): Neutral, No Signal
• Bollinger Bands Weekly: Mildly Bullish; Monthly: Bearish
• OBV Weekly & Monthly: Bullish
• Mojo Score: 45.0 (Sell, downgraded from Hold)

Investors should continue to monitor these technical indicators alongside fundamental developments to navigate Alembic Pharmaceuticals’ evolving market dynamics effectively.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →